Gene therapy - can it cure type 1 diabetes
Open accessAbstract
Type 1 diabetes (T1D) is one of the most prevalent early-onset autoimmune diseases, and numerous treatment regimens have been developed over the years with a mainstay focus on insulin injections, infusions, and pumps. However, with the evolution of modern medicine in the recent decade, can gene therapy be a possible solution to prevent and even cure this autoimmune diabetes? In this review, the authors discuss the present-day advancements around the globe where gene therapy is implemented in different techniques to halt and even reverse T1D. The main focus of the final included studies for this review was to regenerate or preserve pancreatic β cells from other cell types in order to optimize insulin secretions in non-obese autoimmune diabetic patients. A literature search was done in various databases such as PubMed, ScienceDirect, and Google Scholar, and a final of eight studies were included. On the whole, the studies reviewed suggested favorable results of gene therapy, although these researches were done mainly in vitro or as animal studies. The application of different virus vector encoding gene transfer through transcription factors, mRNA electroporation, insulin-like growth factor gene expression as well as combination gene transfer concluded beneficial effects on normalizing insulin production, which could pave the path to perfecting gene therapy, and may even find a permanent cure for T1D in the near future.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Preclinical research shows that gene therapy can be applied in various ways and preserves pancreatic β-cells, which optimizes insulin secretion levels.
“Research conducted on animals (preclinical) shows that gene therapy can be applied in various ways and preserves pancreatic β-cells, which optimizes insulin secretion levels.”
From A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. (2024) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 14
- [1]Type 1 diabetes - a clinical perspective Point Care Kahanovitz L Sluss PM Russell SJ 37 40 16 2017 28943810 PMC5606981
- [2]Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing Int J Vasc Med Kolluru GK Bir SC Kevil CG 918267 2012 2012 22611498 PMC3348526
- [3]Early diabetes-related complications in children and adolescents with type 1 diabetes: implications for screening and intervention Endocrinol Metab Clin North Am Sochett E Daneman D 865 882 28 1999 10609124
- [4]Dual-hormone artificial pancreas for management of type 1 diabetes: recent progress and future directions Artif Organs Infante M Baidal DA Rickels MR Fabbri A Skyler JS Alejandro R Ricordi C 968 986 45 2021 34263961 PMC9059950
- [5]Correction of diabetic hyperglycemia and amelioration of metabolic anomalies by minicircle DNA mediated glucose-dependent hepatic insulin production PLoS One Alam T Wai P Held D Vakili ST Forsberg E Sollinger H 0 8 2013 PMC3694888 23826312
- [7]Reg3g overexpression promotes β cell regeneration and induces immune tolerance in nonobese-diabetic mouse model J Leukoc Biol Xia F Cao H Du J Liu X Liu Y Xiang M 1131 1140 99 2016 26667474
- [8]Promoter optimisation of lentiviral vectors for efficient insulin gene expression in canine mesenchymal stromal cells: potential surrogate beta cells J Gene Med Gautam P Recino A Foale RD 312 321 18 2016 27572655
- [9]Adoptive transfer of mRNA-transfected T cells redirected against diabetogenic CD8 T cells can prevent diabetes Mol Ther Fishman S Lewis MD Siew LK 456 464 25 2017 28109957 PMC5368593
- [10]Mafa enables Pdx1 to effectively convert pancreatic islet progenitors and committed islet α-cells into β-cells in vivo Diabetes Matsuoka TA Kawashima S Miyatsuka T 1293 1300 66 2017 28223284 PMC5399608
- [11]AAV-mediated pancreatic overexpression of Igf1 counteracts progression to autoimmune diabetes in mice Mol Metab Mallol C Casana E Jimenez V 664 680 6 2017 28702323 PMC5485311
- [12]Anti-TCRβ mAb in combination with neurogenin3 gene therapy reverses established overt type 1 diabetes in female NOD mice Endocrinology Xie A Li R Jiang T 3140 3151 158 2017 28977608 PMC5659705
- [13]Avidity and bystander suppressive capacity of human regulatory T cells expressing de novo autoreactive T-cell receptors in type 1 diabetes Front Immunol Yeh WI Seay HR Newby B 1313 8 2017 29123516 PMC5662552
- [14]Endogenous reprogramming of alpha cells into beta cells, induced by viral gene therapy, reverses autoimmune diabetes Cell Stem Cell Xiao X Guo P Shiota C 78 90 22 2018 29304344 PMC5757249
- [15]Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research Acta Physiol Scand Gehl J 437 447 177 2003 12648161
Cited by
Sorted by citations
Tegegne, B. A., Adugna, A., Yenet, A., Yihunie Belay, W., Yibeltal, Y., Dagne, A., Hibstu Teffera, Z., Amare, G. A., Abebaw, D., Tewabe, H., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1440456 · Cited by 61 · see citing works
“Another method is to create insulin-producing cells in the liver by gene transfer using anti-TCR b mAb and Ngn3-Btc (116).”
BackgroundMethodInfluential
- Authors
- Srinivasan, M., Thangaraj, S. R., & Arzoun, H.
- Affiliations
- California Institute of Behavioral Neurosciences and Psychology (United States) (US)
- Corresponding author
- Srinivasan, Mirra
- ORCID
- Srinivasan, Mirra
- Venue
- Cureus
- Published
- 2021-12-19
- Volume
- 13
- Issue
- 12
- Pages
- e20516-e20516
- ISSN
- 2168-8184 (ISSN-L)
- PMC
- PMC8723777
- OpenAlex
- W4200153568
- Cited by
- 11
- References
- 0
- Citations by year
- 2025: 5 · 2024: 5 · 2023: 1
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Cureus (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- type 1 diabetes, gene therapy, pancreatic beta-cell regeneration, beta-cell preservation, insulin secretion, viral vectors, transcription factors, mRNA electroporation, insulin-like growth factor, autoimmune disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
